A second-generation 99mtechnetium single photon emission computed tomography agent that provides in vivo images of the dopamine transporter in primate brain

Journal of Medicinal Chemistry

Volumn 46, Issue 16, 2003, Pages 3483-3496

  Meltzer, Peter C ^a   Blundell, Paul ^a   Zona, Thomas ^a   Yang, Lihua ^a   Huang, Hong ^a   Bonab, Ali A ^b   Livni, Eli ^b   Fischman, Alan ^b   Madras, Bertha K ^c  

^a ORGANIX INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; N [[2 [[3' N' PROPYL 3'' ALPHA (4 FLUOROPHENYL)TROPANE 2'' BETA 1 PROPANOYL](2 MERCAPTOETHYL)AMINO]ACETYL] 2 AMINOETHANETHIOLATO]TECHNETIUM OXIDE; TECHNETIUM 99M; TECHNETIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; IMAGING; MACACA; MALE; NONHUMAN; QUANTITATIVE ASSAY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; LIGANDS; MACACA FASCICULARIS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; PROTEIN BINDING; RADIOPHARMACEUTICALS; STEREOISOMERISM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0042343838     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0301484     Document Type: Article

References (54)

1. Madras, B. K. Imaging the dopamine transporter: a window on dopamine neurons. In Advances in Neurodegenerative Disorders. Parkinson's Disease; Marwah, J., Teitelbaum, H., Eds.; 1998; pp 229-253.
2. 3H]-Lu19-005: markers for cocaine receptors/dopamine nerve terminals in Parkinson's disease. Soc. Neurosci. Abstr. 1990, 16, 14.
3. Kaufman, M. J.; Madras, B. K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991, 9, 43-49.
4. Dougherty, D. D.; Bonab, A. A.; Spencer, T. J.; Rauch, S. L.; Madras, B. K.; Fischman, A. J. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999, 354, 2132-2133.
5. Krause, K.-H.; Dresel, S. H.; Krause, J.; Kung, H. F.; Tatsch, K. Increased striatal dopamine transporter in adult patients with attention deficit disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. 2000, 285, 107-110.
6. 123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur. J. Med. Chem. 1997, 24, 68-71.
7. Morgan, G. F.; Nowotnik, D. P. Development of dopamine transporter imaging agents for the diagnosis of Parkinson's disease. Drug News Persect. 1999, 12, 137-145.
8. Elmaleh, D. A.; Fischman, A. J.; Shoup, T. M.; Byon, C.; Hanson, R. N.; Liang, A. Y.; Meltzer, P. C.; Madras, B. K. Preparation and biological evaluation of iodine-125-IACFT: A selective SPECT agent for imaging dopamine transporter sites. J. Nucl. Med. 1996, 37, 1197-1202.
9. Meltzer, P. C.; Blundell, P.; Jones, A. G.; Mahmood, A.; Garada, B.; Zimmerman, R. E.; Davison, A.; Holman, B. L.; Madras, B. K. A Technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J. Med. Chem. 1997, 40, 1835-1844.
10. Kung, H. F.; Kim, H.-J.; Kung, M.-P.; Meegalla, S. K.; Plössl, K.; Lee, H.-K. Imaging of the dopamine transporters in humans with technetium-99m TRODAT-1. Eur. J. Nucl. Med. 1996, 23, 1527-1530.
11. Meegalla, S. K.; Plössl, K.; Kung, M.-P.; Chumpradit, S.; Stevenson, D. A.; Kushner, S. A.; McElgin, W. T.; Mozley, P. D.; Kung, H. F. Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J. Med. Chem. 1997, 40, 9-17.
12. Hom, R. K.; Katzenellenbogen, J. A. Technetium-99m-labelled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl. Med. Biol. 1997, 24, 485-498.
13. Hoepping, A.; Reisgys, M.; Brust, P.; Seifert, S.; Spies, H.; Alberto, R.; Johannsen, B. TROTEC-1: A new high-affinity ligand for labeling the dopamine transporter. J. Med. Chem. 1998, 41, 4429-4432.
14. Tamagnan, G.; Gai, Y.; Baldwin, R. M.; Zoghbi, S. S.; Neumeyer, J. L. Synthesis of β-CIT-BAT, a potential technetium-99m imaging ligand for the dopamine transporter. Tetrahedron Lett. 1996, 37, 4353-4356.
15. Neumeyer, J. L.; Wang, S.; Gao, Y.; Milius, R. A.; Kula, N. S.; Campbell, A.; Baldessarini, R. J.; Zea-Ponce, Y.; Baldwin, R. M.; Innis, R. B. N-ω-Fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT): Radiotracers for positron emission computed tomography imaging of dopamine transporters. J. Med. Chem. 1994, 37, 1558-1561.
16. 123I]3β-(4-Iodophenyl)tropan-2-carboxylic acid methyl ester (RTI-55), a unique cocaine receptor ligand for imaging the dopamine and serotonin transporters in vivo. Med. Chem. Res. 1991, 1, 289-294.
17. Abi-Dargham, A.; Gandelman, M. S.; DeErausquin, G. A.; Zea-Ponce, Y.; Zoghbi, S. S.; Baldwin, R. M.; Laruelle, M.; Charney, D. S.; Hoffer, P. B.; Neumeyer, J. L.; Innis, R. B. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J. Nucl. Med. 1996, 37, 1129-1133.
18. Fischman, A. J.; Babich, J. W.; Elmaleh, D. R.; Meltzer, P. C.; Barrow, S. A.; Madras, B. K. SPECT imaging of dopamine transporter sites in normal and MPTP treated Rhesus monkeys. J. Nucl. Chem. 1995, 36, 87.
19. Fischman, A. J.; Babich, J. W.; Elmaleh, D. R.; Barrow, S. A.; Meltzer, P. C.; Hanson, R. N.; Madras, B. K. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys. J. Nucl. Med. 1997, 38, 144-150.
20. 123I]IACFT): initial experience in humans. Neurosci.-Net 1997, 1, 00010.
21. Fischman, A. J.; Bonab, A. A.; Babich, J. W.; Palmer, E. P.; Alpert, N. M.; Elmahleh, D. R.; Callahan, R. J.; Barrow, S. A.; Graham, W.; Meltzer, P. C.; Hanson, R. N.; Madras, B. K. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998, 29, 128-141.
22. Madras, B. K.; Gracz, L. M.; Fahey, M. A.; Elmahleh, D. R.; Meltzer, P. C.; Liang, A. Y.; Stopa, E. G.; Babich, J. W.; Fischman, A. J. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in post-mortem normal and Parkinson's diseased brain. Synapse 1998, 29, 116-127.
23. Bonab, A. A.; Alpert, N. M.; Livni, E.; Meltzer, P. C.; Madras, B. K.; Fischman, A. J. Human DAT binding measurement with 11C-altropane. J. Nucl. Med. 2001, 42, 184.
24. Fischman, A. J.; Bonab, A. A.; Livni, E.; Meltzer, P. C.; Barrow, S. A.; Madras, B. K. Evaluation of dopamine transporter (DAT) density in patients with Parkinson's disease (PD) by PET with 1271, 11C altropane. J. Nucl. Med. 2002, 18, 43.
25. Rao, T. N.; Adhikesvalu, D.; Camerman, A.; Fritzberg, A. R. Technetium(V) and rhenium(V) complexes of 2,3-bis(mercaptoacetamido)propanoate. Chelate ring stereochemistry and influence on chemical and biological properties. J. Am. Chem. Soc. 1990, 112, 5798-5804.
26. Stepniak-Biniakiewicz, D.; Chen, B.; Deutch, E. A new general synthetic route to multidentate N,S ligands for use in technetium-99m radiopharmaceuticals. J. Med. Chem. 1992, 35, 274-279.
27. Lever, S. Z.; Burns, H. D.; Kervitsky, T. M.; Goldfarb, H. N.; Woo, D. V.; Wong, D. F.; Epps, L. A.; Kramer, A. V.; Wagner, H. N. Design, preparation, and biodistribution of a technetium-99m triaminedithiol complex to assess regional cerebral blood flow. J. Nucl. Med. 1985, 26, 1287-1294.
28. Jones, A. G.; Abrams, M. J.; Davison, A.; Brodack, J. W.; Toothaker, A. K.; Aldelstein, S. J.; Kassis, A. I. Biological studies of a new class of technetium complexes: The hexakis-(alkylisonitrile)-technetium(I) cations. Int. J. Nucl. Med. Biol. 1984, 11, 225-234.
29. 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996, 22, 239-246.
30. Meegalla, S.; Plössl, K.; Kung, M.-P.; Chumpradit, S.; Stevenson, D. A.; Frederick, D.; Kung, H. F. Tc-99m-Labelled tropanes as dopamine transporter imaging agents. Bioconjugate Chem. 1996, 7, 421-429.
31. Mach, R. M.; Wheeler, K. T.; Blair, S.; Yang, B.; Day, C. S.; Blair, J. B.; Choi, S.-R.; Kung, H. F. Preparation of a technetium-99m SPECT agent for imaging the sigma-2 receptor status of solid tumors. J. Labelled Compd. Radiopharm. 2001, 44, 899-908.
32. Meltzer, P. C.; Blundell, P.; Madras, B. K. Structure activity relationships of inhibition of the dopamine transporter by 3-arylbicyclo [3.2.1]octanes. Med. Chem. Res. 1998, 8, 12-34.
33. Meltzer, P. C.; Liang, A. Y.; Brownell, A.-L.; Elmaleh, D. R.; Madras, B. K. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J. Med. Chem. 1993, 36, 855-862.
34. Bonab, A. A.; Meltzer, P. C.; Hillier, S.; Barrow, S. A.; Madras, B. K.; Fischman, A. J. Quantification of SPECT imaging with a highly selective DAT ligand 99mTc-O-1505. J. Nucl. Med. 2000, 41, 185.
35. Bonab, A. A.; Meltzer, P. C.; Alpert, N. M.; Burker, M.; Dragotakes, S. D.; Barrow, B.; Madras, B. K.; Fischman, A. J. Human brain SPECT imaging with a highly selective DAT ligand 99mTc-O-1505T. J. Nucl. Med. 2001, 42, 210.
36. Hillier, S.; Burker, M.; Meltzer, P. C.; Madras, B. K.; Fischman, A. J. Radiolabeling of the highly selective DAT ligand, Tc-O-1505, with 99mTc. Choice of transchelation agent. J. Nucl. Med. 2000, 41, 185.
37. DiZio, J. P.; Fiaschi, R.; Davison, A.; Jones, A.; Katzenellenbogen, J. A. Progestins-rhenium complexes: metal-labeled steroids with receptor binding affinity, potential receptor-directed agents for diagnostic imaging therapy. Bioconjugate Chem. 1991, 2, 353-366.
38. vO (M = Tc, Re) amine-thiol complexes containing a pendant phenylpiperidine group. Inorg. Chem. 1993, 32, 3114-3124.
39. Holmquist, C. R.; Keverline-Frantz, K. I.; Abraham, P.; Boja, J. W.; Kuhar, M. J.; Carroll, F. I. 3α-(4′-Substituted phenyl)-tropane-2β-carboxylic acid methyl esters: Novel ligands with high affinity and selectivity at the dopamine transporter. J. Med. Chem 1996, 39, 4139-4141.
40. Findlay, S. P. Concerning 2-Carbomethoxytropinone. J. Org. Chem. 1957, 22, 1385-1393.
41. Meltzer, P. C.; Liang, A. Y.; Madras, B. K. The discovery of an unusually selective and novel cocaine analog: Difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J. Med. Chem. 1994, 37, 2001-2010.
42. Basha, A.; Lipton, M.; Weinreb, M. A mild, general method for conversion of esters to amides. Tetrahedron Lett. 1977, 48, 4171-4174.
43. O'Neil, J. P.; Wilson, S. R.; Katzenellenbogen, J. A. Preparation and structural characterization of monoamine-monoamide bis-(thiol) oxo complexes of technetium(V) and rhenium(V). Inorg. Chem. 1994, 33, 319-323.
44. DiZio, J. P.; Anderson, C. J.; Davison, A.; Ehrhardt, G. J.; Carlson, K. E.; Welch, M. J.; Katzenellenbogen, J. A. Technetium and rhenium labeled progestins: synthesis, receptor binding and in vivo distribution of an 11β-substituted progestin labeled with technetium-99 and rhenium-186. J. Nucl. Med. 1992, 33, 558-569.
45. Wolf, J. Synthesis and study of technetium (V) complexes of tetradentate nitrogen, sulfur donor ligands. Ph.D. Thesis, MIT, Cambridge, MA, 1991.
46. 3H] Cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 1989, 251, 131-141.
47. Kozikowski, A. P.; Roberti, M.; Xiang, L.; Bergmann, J. S.; Callahan, P. M.; Cunningham, K. A.; Johnson, K. M. Structure-activity relationship studies of cocaine: replacement of the C-2 ester group by vinyl argues against H-bonding and provides an esterase-resistant, high-affinity cocaine analogue. J. Med. Chem. 1992, 35, 4764-4766.
48. Davies, H. M. L.; Saikali, E.; Sexton, T.; Childers, S. R. Novel 2-substituted cocaine analogs: binding properties at dopamine transport sites in rat striatum. Eur. J. Pharmacol., Mol. Pharm. 1993, 244, 93-97.
49. Kozikowski, A. P.; Roberti, M.; Johnson, K. M.; Bergmann, J. S.; Ball, R. G. SAR of Cocaine: further exploration of structural variations at the C-2 center provides compounds of subnanomolar binding potency. Bioorg. Med. Chem. Lett. 1993, 3, 1327-1332.
50. Carroll, F. I.; Mascarella, S. W.; Kuzemko, M. A.; Gao, Y.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Synthesis, ligand binding, and QSAR (CoMFA and classical) study of 3β-(3′-substituted phenyl)-, 3β-(4′-substituted phenyl)-, 3β-(3′,4′-disubstitutedphenyl)tropane-2β-carboxylic acid methyl esters. J. Med. Chem. 1994, 37, 2865-2873.
51. Xu, L.; Kelkar, S, V.; Lomenzo, S. A.; Izenwasser, S.; Katz, J. L.; Kline, R. H.; Trudell, M. L. Synthesis, dopamine transporter affinity, dopamine uptake inhibition, and locomotor stimulant activity of 2-substituted 3β-phenyltropane derivatives. J. Med. Chem. 1997, 40, 858-863.
52. Davies, H. M. L.; Saikali, E.; Huby, N. J. S.; Gilliatt, V. J.; Matasi, J. J.; Sexton, T.; Childers, S. R. Synthesis of 2β-acyl-3β-aryl-8-azabicyclo[3.2.1]octanes and their binding affinities at dopamine and serotonin transport sites in rat striatum and frontal cortex. J. Med. Chem. 1994, 37, 1262-1268.
53. Keverline, K. I.; Abraham, P.; Lewin, A. H.; Carroll, F. I. Synthesis of the 2β,3α- and 2β,3β-isomers of 3-(p-substituted phenyl)tropane-2-carboxylic acid methyl esters. Tetrahedron Lett. 1995, 36, 3099-3102.
54. Clarke, R. L.; Daum, S. J.; Gambino, A. J.; Aceto, M. D.; Pearl, J.; Levitt, M.; Cumiskey, W. R.; Bogado, E. F. Compounds affecting the central nervous system. 4. 3β-Phenyltropane-2-carboxylic esters and analogs. J. Med. Chem. 1973, 16, 1260-1267.